During the past decade, UCLA Division of Rheumatology conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 7 clinical trials were completed, i.e. on average, 53.8% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 6 clinical trials were completed. i.e. 85.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UCLA Division of Rheumatology" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 7 trials, followed by "Celgene" with 2 trials sponsored, "Galapagos NV" with 2 trials sponsored, "NYU Langone Health" with 2 trials sponsored and "Actelion" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UCLA Division of Rheumatology" #1 collaborator was "Autoimmunity Centers of Excellence" with 3 trials as a collaborator, "Rho Federal Systems Division, Inc." with 3 trials as a collaborator, "Immune Tolerance Network (ITN)" with 2 trials as a collaborator, "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)" with 2 trials as a collaborator and "Office of Research on Women's Health (ORWH)" with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "UCLA Division of Rheumatology" are "Systemic Lupus Erythematosus" (5 trials), "Systemic Sclerosis" (4 trials), "Diffuse Cutaneous Systemic Sclerosis" (3 trials), "Lupus Erythematosus, Systemic" (2 trials) and "Lupus Nephritis" (2 trials). Many other conditions were trialed in "UCLA Division of Rheumatology" in a lesser frequency.

Most popular intervention types in "UCLA Division of Rheumatology" are "Drug" (16 trials), "Biological" (5 trials), "Other" (2 trials), "Device" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "GLPG1690" (2 trials), "1.2% Sodium Hyaluronate" (1 trials), "Acetaminophen" (1 trials) and "Ad26.COV2.S" (1 trials). Other intervention names were less common.

The vast majority of trials in "UCLA Division of Rheumatology" are 20 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "UCLA Division of Rheumatology". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in UCLA Division of Rheumatology, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in UCLA Division of Rheumatology, 4 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".